Summary of findings: insulin detemir vs NPH insulin
- (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes onlyno estimate extracted8 studies · 3122 participantsModerate
Summary of findings: insulin glargine showed no clear difference in severe hypoglycaemia (n/N) Definition: symptomatic hypoglycaemia… compared with NPH insulin (moderate certainty).
Summary of findings: insulin glargine showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with NPH insulin (moderate certainty).
Summary of findings: insulin glargine showed no clear difference in serious adverse events (n/N) compared with NPH insulin (moderate certainty).
Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin detemir (low certainty).
Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin detemir (low certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).
It is very uncertain whether summary of findings: insulin degludec changes all‐cause mortality compared with insulin glargine (very low certainty).
Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin glargine (low certainty).
Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin glargine (low certainty).
Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin glargine (low certainty).